Orally administered treatment for age-related macular degeneration Macular degeneration is a major cause of blindness in the elderly → High unmet medical needs due to the limitations of existing treatments

Age-Related Macular Degeneration
Age-related macular degeneration is an ocular disease that causes visual impairment due to aging and changes to the macula lutea, which is located in the center of the inner retina.
Age-related macular degeneration is a major cause of blindness in people over 60
Wet and dry macular degeneration

Existing medicine and unmet medical needs

Global market perspective

Orally administered treatment for age-related macular degeneration Phase 2a clinical trial study design

Study overview

Design: Multi-center, randomized, double-blind, placebo-control
ObjectivesTo evaluate tolerability, safety and efficacy arm
Number of subjects3groups(treatment arm I, II and placebo arm)

Study schedule

04-Dec-2019 : IND approved(Ministry of Food and Drug Safety)
Dec-2019 : IRB approved & Site initiation visit
13-Mar-2020 : First Patient In
04-Sep-2020 : Tolerability assessment
31-Mar-2021 : Achievement for subject recruiting rate 97%

Orally administered treatment for age-related macular degeneration